AstraZeneca ($AZN) announced an update on their ongoing clinical study. AstraZeneca recently completed a clinical study titled ‘A Multiple Centre, ...
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved ...
PE: How are global regulatory agencies adjusting their policies for biosimilars? Woollett: The clear leaders in the space of biosimilar development have been the European agency, the UK, and US FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback